JP2016527221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527221A5 JP2016527221A5 JP2016526518A JP2016526518A JP2016527221A5 JP 2016527221 A5 JP2016527221 A5 JP 2016527221A5 JP 2016526518 A JP2016526518 A JP 2016526518A JP 2016526518 A JP2016526518 A JP 2016526518A JP 2016527221 A5 JP2016527221 A5 JP 2016527221A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- targeting moiety
- mutant
- beta
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306047.5 | 2013-07-19 | ||
| EP13306047 | 2013-07-19 | ||
| PCT/EP2014/064283 WO2015007542A1 (en) | 2013-07-19 | 2014-07-04 | Targeted modified il-1 family members |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527221A JP2016527221A (ja) | 2016-09-08 |
| JP2016527221A5 true JP2016527221A5 (enExample) | 2017-08-10 |
| JP6475713B2 JP6475713B2 (ja) | 2019-02-27 |
Family
ID=48874235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526518A Active JP6475713B2 (ja) | 2013-07-19 | 2014-07-04 | 標的修飾ｉｌ−１ファミリーメンバー |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9932409B2 (enExample) |
| EP (1) | EP3022226B1 (enExample) |
| JP (1) | JP6475713B2 (enExample) |
| KR (1) | KR102275090B1 (enExample) |
| CN (1) | CN105612180B (enExample) |
| AU (1) | AU2014292377B2 (enExample) |
| BR (1) | BR112016001128A2 (enExample) |
| CA (1) | CA2918518C (enExample) |
| DK (1) | DK3022226T3 (enExample) |
| ES (1) | ES2714504T3 (enExample) |
| IL (1) | IL243466B (enExample) |
| MX (1) | MX370348B (enExample) |
| SG (1) | SG11201600167SA (enExample) |
| WO (1) | WO2015007542A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017075537A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| CN108472365A (zh) | 2015-10-30 | 2018-08-31 | 艾丽塔生物治疗剂公司 | 用于肿瘤转导的组合物和方法 |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| EP4276114A3 (en) | 2016-03-07 | 2024-02-21 | Vib Vzw | Cd20 binding single domain antibodies |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| JP7204643B2 (ja) | 2016-10-24 | 2023-01-16 | オリオニス バイオサイエンシズ ビーブイ | 標的変異インターフェロン－ガンマおよびその使用 |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| CN110913954A (zh) * | 2017-03-03 | 2020-03-24 | 黑曜石疗法公司 | 免疫疗法的组合物和方法 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| BR112020002706A2 (pt) | 2017-08-09 | 2020-08-25 | Orionis Biosciences Inc. | agentes de ligação a clec9a e uso dos mesmos |
| WO2019032661A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
| WO2019129053A1 (zh) * | 2017-12-26 | 2019-07-04 | 南京金斯瑞生物科技有限公司 | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 |
| WO2019148089A1 (en) | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| CN112074267B (zh) | 2018-02-05 | 2024-06-28 | 奥里尼斯生物科学公司股份有限公司 | 成纤维细胞结合剂及其用途 |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| CA3118892A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| US12544426B2 (en) | 2019-06-19 | 2026-02-10 | Orionis Biosciences, Inc. | Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| US20230293652A1 (en) * | 2020-07-07 | 2023-09-21 | Orionis Biosciences, Inc. | Immunostimulatory adjuvants |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3115318B2 (ja) | 1989-08-22 | 2000-12-04 | イミュネックス・コーポレーション | Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) * | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| WO2001029870A1 (en) * | 1999-10-21 | 2001-04-26 | Sarnoff Corporation | Bi-potential electrode space-saving cathode ray tube |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| CA2693326A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Gm-csf and il-15 fusokines and methods for modulation of the immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| EP2173377B1 (en) * | 2007-06-26 | 2017-11-29 | University of Miami | Antibody-endostatin fusion protein and its variants |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| PE20120630A1 (es) * | 2009-08-17 | 2012-05-26 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| JP2013504539A (ja) * | 2009-09-10 | 2013-02-07 | サイトス バイオテクノロジー アーゲー | 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用 |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| AU2013211059B8 (en) | 2012-01-20 | 2017-12-21 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted mutant alpha-helical bundle cytokines |
| CA2866126A1 (en) | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
-
2014
- 2014-07-04 DK DK14735574.7T patent/DK3022226T3/en active
- 2014-07-04 AU AU2014292377A patent/AU2014292377B2/en active Active
- 2014-07-04 MX MX2016000723A patent/MX370348B/es active IP Right Grant
- 2014-07-04 KR KR1020167002679A patent/KR102275090B1/ko active Active
- 2014-07-04 EP EP14735574.7A patent/EP3022226B1/en active Active
- 2014-07-04 JP JP2016526518A patent/JP6475713B2/ja active Active
- 2014-07-04 ES ES14735574T patent/ES2714504T3/es active Active
- 2014-07-04 US US14/905,352 patent/US9932409B2/en active Active
- 2014-07-04 WO PCT/EP2014/064283 patent/WO2015007542A1/en not_active Ceased
- 2014-07-04 BR BR112016001128-7A patent/BR112016001128A2/pt not_active Application Discontinuation
- 2014-07-04 SG SG11201600167SA patent/SG11201600167SA/en unknown
- 2014-07-04 CN CN201480040652.6A patent/CN105612180B/zh active Active
- 2014-07-04 CA CA2918518A patent/CA2918518C/en active Active
-
2016
- 2016-01-05 IL IL24346616A patent/IL243466B/en active IP Right Grant
-
2018
- 2018-02-21 US US15/901,545 patent/US20180186894A1/en not_active Abandoned
-
2019
- 2019-03-21 US US16/360,793 patent/US20190202934A1/en not_active Abandoned
-
2020
- 2020-04-28 US US16/860,660 patent/US20200255545A1/en not_active Abandoned
-
2023
- 2023-02-01 US US18/163,026 patent/US20230235086A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529232A5 (enExample) | ||
| MX2020013062A (es) | Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso. | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| EP4276114A3 (en) | Cd20 binding single domain antibodies | |
| CY1124456T1 (el) | Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων | |
| MX370348B (es) | Miembros de la familia il-1 modificados dirigidos. | |
| WO2012149412A3 (en) | Anti-endoglin (cd105) antibodies, immunoconjugates, and uses thereof | |
| TN2014000434A1 (en) | St2 antigen binding proteins | |
| MX384026B (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
| HK1250513A1 (zh) | 抗ox40抗体及其使用方法 | |
| NZ626610A (en) | Antibodies that bind csf1r | |
| EA201200549A1 (ru) | Dll4-связывающие молекулы | |
| EP4183806A3 (en) | Glycan-interacting compounds and methods of use | |
| EA201300311A1 (ru) | Vegf-связывающие молекулы | |
| BR112012024713A2 (pt) | "anticorpo humanizado, anticorpo monoclonal humanizado ou fragmento de anticorpo, seus usos, polinucleotídeo isolado, e composição farmacêutica" | |
| WO2015108998A3 (en) | Cartilage targeting agents and their use | |
| JP2016525516A5 (enExample) | ||
| NZ602166A (en) | Antibodies to il-6 and use thereof | |
| BR112012028920A2 (pt) | formulações de anticorpo de alta concentração | |
| EP4311558A3 (en) | Antibodies that bind il-23 | |
| WO2015069794A3 (en) | Novel anti-claudin antibodies and methods of use | |
| HRP20221490T1 (hr) | Poboljšanje antitumorskog odgovora t stanice | |
| WO2015089449A3 (en) | Novel anti-dpep3 antibodies and methods of use | |
| EA201401065A1 (ru) | Ang2-связывающие молекулы | |
| MX2019010458A (es) | Anticuerpos anti-gitr y metodos de uso de los mismos. |